Coencapsulation of doxorubicin and curcumin in liposomes modified with folic acid for reversal of drug resistance in glioma
-
By
-
Zhan Wang
-
Ze Zhao
-
Yang Yang
-
Yi Zhao
-
June 17, 2026
-
Clinical Scorecard: Folic Acid-Modified Liposomes for Coencapsulation of Doxorubicin and Curcumin to Combat Drug Resistance in Glioma
At a Glance
| Category | Detail |
|---|
| Condition | Glioma |
| Key Mechanisms | P-glycoprotein (P-gp) mediated drug efflux and blood-brain barrier (BBB) penetration |
| Target Population | Patients with glioma exhibiting multidrug resistance |
| Care Setting | Oncology and neurology |
Key Highlights
- Dox/Cur-Lip@FA demonstrated 3.56-fold higher cellular uptake in Dox-resistant C6 cells compared to non-targeted formulations.
- FA modification significantly enhanced transendothelial transport in an in vitro BBB model.
- Dox/Cur-Lip@FA induced a 71.19% reduction in tumor volume in vivo, outperforming free drugs and non-targeted liposomes.
- Curcumin effectively suppressed P-gp expression, restoring Dox sensitivity.
- The system combines active targeting with MDR reversal for improved glioma treatment.
Guideline-Based Recommendations
Diagnosis
- Assess glioma type and resistance mechanisms, particularly P-gp expression.
Management
- Utilize Dox/Cur-Lip@FA for targeted delivery in patients with Dox-resistant glioma.
Monitoring & Follow-up
- Monitor tumor response and P-gp expression levels during treatment.
Risks
- Consider potential off-target effects and systemic toxicity from P-gp inhibitors.
Patient & Prescribing Data
Patients with glioma and documented doxorubicin resistance.
Dox/Cur-Lip@FA offers a dual approach by enhancing drug delivery and reversing resistance mechanisms.
Clinical Best Practices
- Incorporate folic acid-targeted therapies in treatment plans for glioma.
- Evaluate the use of curcumin as a chemosensitizer in conjunction with doxorubicin.
Related Resources & Content
